Hydromorphone
| Evidence Level: L4 | Predicted Indications: 6 |
Table of Contents
Hydromorphone: From Severe Pain Management to Pharyngitis
One-Sentence Summary
Hydromorphone is a potent opioid analgesic (μ-opioid receptor agonist) used for management of moderate-to-severe pain. The TxGNN model predicts it may be effective for Pharyngitis, but the 6 clinical trials returned by the evidence search largely involve different drugs (palifermin, methadone) rather than hydromorphone itself, and no supporting literature was identified.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in this evidence pack (opioid analgesic class use inferred from mechanism notes only) |
| Predicted New Indication | Pharyngitis |
| TxGNN Prediction Score | 99.81% |
| Evidence Level | L4 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data for hydromorphone is not available in this evidence pack. Based on information within the evidence itself, hydromorphone is a strong μ-opioid receptor agonist providing systemic analgesia; it has no established anti-infective or anti-inflammatory activity.
Pharyngitis is predominantly a viral or bacterial infective/inflammatory condition of the throat. There is no pharmacological pathway by which a systemic opioid analgesic would treat the underlying disease process, only its symptom (pain).
Critically, of the 6 clinical trials returned by the search for this drug–disease pair, only 2 actually involve hydromorphone, and none study hydromorphone as a treatment for pharyngitis — they concern post-tonsillectomy pain control or unrelated conditions (GVHD-associated oral mucositis, foot/ankle surgery anaesthesia). The remaining trials involve palifermin or methadone, not hydromorphone. This pattern suggests the prediction and its associated trial evidence likely arose from a knowledge-graph entity mapping artefact (anatomical overlap with “pharynx”/”throat” terms) rather than a genuine pharmacological signal.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrolment | Key Findings |
|---|---|---|---|---|
| NCT00189488 | Phase 2 | Completed | 155 | Palifermin (not hydromorphone) vs placebo for acute GVHD/oral mucositis — drug mismatch, not directly relevant |
| NCT05244226 | Phase 2 | Completed | 66 | Methadone vs fentanyl/hydromorphone for pain after paediatric tonsillectomy — pain control study, not a pharyngitis treatment trial |
| NCT00109031 | Phase 3 | Completed | 47 | Palifermin dosing schedule for oral mucositis prevention — drug mismatch, not directly relevant |
| NCT04230681 | Early Phase 1 | Completed | 189 | RCT of hydromorphone vs fentanyl for pain control after tonsillectomy/adenotonsillectomy in children — involves the target drug but addresses post-surgical pain, not pharyngitis as a disease |
| NCT06576830 | Phase 4 | Recruiting | 440 | Single-dose intraoperative methadone vs fentanyl/hydromorphone for paediatric tonsillectomy pain — drug and indication mismatch |
| NCT02996591 | Phase 4 | Completed | 36 | Spinal vs general anaesthesia with nerve blocks for foot and ankle surgery — unrelated to pharyngitis or hydromorphone’s proposed use |
Literature Evidence
Currently no related literature available.
UK Market Information
No UK marketing authorisation is currently recorded for Hydromorphone in this evidence pack (market status: Not marketed; 0 licences on file).
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Conclusion and Next Steps
Decision: Hold
Rationale: The mechanistic basis for using hydromorphone in pharyngitis is not plausible (systemic opioid analgesic vs. an infective/inflammatory throat condition), and the clinical trial evidence returned is largely a mismatch — most trials involve different drugs (palifermin, methadone) or unrelated surgical pain indications rather than hydromorphone treating pharyngitis directly. No supporting literature exists. This pattern is consistent with a knowledge-graph mapping artefact rather than a genuine repurposing signal.
To proceed, the following is needed:
- MHRA-approved product labelling / SmPC data (DG001, blocking) — required before any safety assessment can proceed
- Confirmed mechanism of action data from DrugBank (DG002, high priority)
- A revised, disease-specific literature and trial search to rule out the entity-mapping artefact before further evaluation
Note: This evidence pack also contains a considerably stronger repurposing signal elsewhere in the ranked list — hydromorphone for headache disorder (rank 5, TxGNN score 99.65%, Evidence Level L2, decision stage S2, “Research Question”), supported by a completed Phase 4 RCT directly comparing hydromorphone to prochlorperazine + diphenhydramine for acute migraine (NCT02389829) and 17 literature records including a 2026 American Headache Society guideline update. Reviewers may wish to prioritise that candidate over pharyngitis for further evaluation, noting that current migraine guidelines position opioids only as a last-resort option due to medication-overuse headache and dependence risk.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.